Fatal GvHD induced by PD-1 inhibitor pembrolizumab in a patient with Hodgkin's lymphoma.
Division of Hematologic Malignancies and Cellular Therapeutics, Blood and Marrow Transplantation Program, University of Kansas Medical Center, Westwood, KS, USA.
A K
AK
Singh
Department of Hematology, Mayo Clinic, Rochester, MN, USA.
L F
LF
Porrata
Division of Hematologic Malignancies and Cellular Therapeutics, Blood and Marrow Transplantation Program, University of Kansas Medical Center, Westwood, KS, USA.
O
O
Aljitawi
Division of Hematologic Malignancies and Cellular Therapeutics, Blood and Marrow Transplantation Program, University of Kansas Medical Center, Westwood, KS, USA.
T
T
Lin
Division of Hematologic Malignancies and Cellular Therapeutics, Blood and Marrow Transplantation Program, University of Kansas Medical Center, Westwood, KS, USA.
L
L
Shune
Division of Hematologic Malignancies and Cellular Therapeutics, Blood and Marrow Transplantation Program, University of Kansas Medical Center, Westwood, KS, USA.
S
S
Ganguly
Division of Hematologic Malignancies and Cellular Therapeutics, Blood and Marrow Transplantation Program, University of Kansas Medical Center, Westwood, KS, USA.
J P
JP
McGuirk
Division of Hematologic Malignancies and Cellular Therapeutics, Blood and Marrow Transplantation Program, University of Kansas Medical Center, Westwood, KS, USA.
S
S
Abhyankar
D000328:Adult; D061067:Antibodies, Monoclonal, Humanized / Q000009:adverse effects*; D017809:Fatal Outcome; D006086:Graft vs Host Disease / Q000139:chemically induced* / Q000209:etiology; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects; D006689:Hodgkin Disease / Q000150:complications / Q000628:therapy; D006801:Humans; D008297:Male; D011014:Pneumonia; D061026:Programmed Cell Death 1 Receptor / Q000037:antagonists & inhibitors; D014182:Transplantation, Autologous
D061067:Antibodies, Monoclonal, Humanized; C105992:PDCD1 protein, human; D061026:Programmed Cell Death 1 Receptor; C582435:pembrolizumab